Pervasiveness of malignancy is on the ascent all through the world. Progressed therapeutics are being created by drug organizations to address the developing weight of malignancy.
Pervasiveness of malignancy is on the ascent all through the world. Progressed therapeutics are being created by drug organizations to address the developing weight of malignancy.
The global cancer therapeutics market size was valued at $98.90 billion in 2018, and is projected to reach $180.19 billion by 2026, at a CAGR of 7.7% from 2019-2026.
The market is driven by factors such as development of novel cancer therapeutics and surge in cancer awareness & availability of oncology drugs in the developing markets.
Flood in geriatric populace and ascend in the quantity of coordinated efforts and associations to work with drug advancement are the critical drivers of the global cancer therapeutics market. Also, hefty inflow of interest in R&D exercises has upgraded the improvement of malignant growth therapeutics. Moreover, good unofficial laws for malignant growth therapeutics and flood in disease commonness support the market. The appeal for customized medication alongside high capability of arising economies give rewarding freedoms to the market. In any case, unfavorable impacts identified with cancer therapeutics and significant expenses related with oncology drugs block the development of the cancer therapeutics market.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/480
Covid-19 Scenario-
- The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.
- The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.
- However, as the world has been recovering from the pandemic, the market is estimated to get back on track.
Recent progress in biological therapies have widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/biologics are emerging as the potential therapies to find a permanent cure for various cancer types among various cancer therapeutics.
Among the various applications, cellular breakdown in the lungs almost involved one-fifth offer in the global cancer therapeutics market in 2018. This can be credited to the increment in commonness of cellular breakdown in the lungs in both created and creating economies. Moreover, drug organizations are growing better than ever medications to handle the weight of this sickness.
The cancer therapeutics market trends are analyzed based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America was the leading revenue contributor to the global market in 2018, owing to high adoption rate of cancer therapeutics. North America occupied more than half of the total market share in 2018. However, Asia-Pacific is expected to grow at the highest CAGR of 10.4% from 2019 to 2026, owing to increase in disposable income; surge in research, development, & innovation activities; and growth in awareness of cancer therapeutics.
Increase in competition and continuous technological advancements have led to enhancements in the product portfolio; hence, product approvals and product development are one of the key developmental strategies adopted by the market players in the global cancer therapeutics market. For instance, in November 2017, Merck and Pfizer launched the cancer drug Bavencio (avelumab), in the UK for the treatment of the rare, aggressive skin cancer metastatic Merkel Cell Carcinoma (mMCC). Similarly, in April 2018, the European Commission (EC) approved Pfizer’s Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL).
Similarly, different collaborations and agreements have also shaped the competitive landscape of the global cancer therapeutics industry. In December 2017, Janssen entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, both subsidiaries of Genscript Biotech Corporation, to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA). Likewise, in April 2018, Pfizer and the U.S. based Allogene Therapeutics collaborated to develop donor-derived CAR T-cell therapies.
Access Full Report: https://www.alliedmarketresearch.com/cancer-therapeutics-biotherapeutic-market
The Major Key Players Are:
F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma, Inc., Pfizer, Inc., Novartis AG, Merck KGaA, and Eli Lilly and Company.
Trending Reports:
Apheresis Market - Global Opportunity Analysis and Industry Forecast, 2021–2030
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch (dot) com